trending Market Intelligence /marketintelligence/en/news-insights/trending/euyhP2354WCAn81Lo7RTHg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Medical device maker Silk Road sets price range of Nasdaq IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Medical device maker Silk Road sets price range of Nasdaq IPO

Silk Road Medical Inc. expects to price the IPO of 4,687,500 of its common shares on Nasdaq at between $15 and $17 apiece.

The Sunnyvale, Calif.-based medical-device maker is expected to raise about $75 million in gross proceeds, assuming a per share price of $16. The company has applied to list its common stock on the Nasdaq Global Market under the symbol SILK.

The company intends to use the net proceeds to expand sales force and operations, increase research and development activities, to conduct clinical trials, expand internationally, and for working capital and other general corporate purposes.

Silk Road is focused on developing a treatment called transcarotid artery revascularization for carotid artery disease, one of the leading causes of stroke.

J.P. Morgan Securities LLC, Merrill Lynch Pierce Fenner & Smith Inc., BMO Capital Markets Corp. and Stifel Nicolaus & Co. Inc. are acting as underwriters for the IPO.

Silk Road also granted the underwriters a 30-day option to buy an additional 703,125 shares.